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Retinoids, such as all-trans-retinoic acid (ATRA), regulate cellular differentiation and signalling pathways
in chordates by binding to nuclear retinoic acid receptors (RARa/b/c). Polar interactions between recep-
tor and ligand are important for binding and facilitating the non-polar interactions and conformational
changes necessary for RAR-mediated transcriptional regulation. The constraints on activity and RAR-type
specificity with respect to the structural link between the polar and non-polar functions of synthetic reti-
noids are poorly understood. To address this, predictions from in silico ligand-RAR docking calculations
and molecular dynamics simulations for a small library of stable, synthetic retinoids (designated GZ ser-
ies) containing a central thiazole linker structure and different hydrophobic region substituents, were
tested using a ligand binding assay and a range of cellular biological assays. The docking analysis showed
that these thiazole-containing retinoids were well suited to the binding pocket of RARa, particularly via a
favorable hydrogen bonding interaction between the thiazole and Ser232 of RARa. A bulky hydrophobic
region (i.e., present in compounds GZ23 and GZ25) was important for interaction with the RAR binding
pockets. Ligand binding assays generally reflected the findings from in silico docking, and showed that
GZ25 was a particularly strongly binding ligand for RARa/b. GZ25 also exhibited higher activity as an
inducer of neuronal differentiation than ATRA and other GZ derivatives. These data demonstrate that
GZ25 is a stable synthetic retinoid with improved activity which efficiently regulates neuronal differen-
tiation and help to define the key structural requirements for retinoid activity enabling the design and
development of the next generation of more active, selective synthetic retinoids as potential therapeutic
regulators of neurogenesis.
 2018 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Retinoids are signaling molecules functionally related to all-
trans retinoic acid (ATRA), a metabolite of Vitamin A (Fig. 1).1,2
These small lipophilic molecules mediate cellular proliferation, dif-
ferentiation and homeostasis in chordates3 by acting as ligands formembers of a family of nuclear receptors referred to as retinoic
acid receptors (RARs) and retinoid X receptors (RXRs). Given the
range of biological processes regulated by retinoids, there is huge
potential for synthetic retinoids as therapeutics. However, this
potential has yet to be realized, mainly because of a lack of detailed
understanding of RAR signaling mechanisms in biological pro-
cesses and the design criteria for targeting synthetic retinoids to
specific responses. Furthermore, although retinoic acid is used to
treat a variety of skin conditions, acute promyelocytic leukemia,
neuroblastoma and other cancers and metabolic diseases,4–7 it is
highly susceptible to photodegradation and readily isomerizes to
a mixture of 9-cis-retinoic acid, 13-cis-retinoic acid and other iso-
mers, as well as undergoing decomposition. The development of
stable ATRA analogues is, therefore, of substantial importance for
Fig. 1. Molecular structures of all-trans-retinoic acid (ATRA) and the synthetic thiazole retinoids GZ18, GZ22, GZ23, GZ24 and GZ25, and preferred binding conformation of
ATRA according to previous molecular docking studies.23
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development.8,9
Three closely related isotypes of each of the RARs (and RXRs)
are known, and are designated RARa, RARb, and RARc, respec-
tively.1 They all share the same overall structure, with six domains,
specified A to F.1,10 The A and B domains comprise a ligand
independent activation function (AF-1), responsible for recruiting
coactivators necessary for gene regulation.11 The DNA-binding
C domain12,13 is linked, via a hinge domain D, to the ligand-binding
domain (LBD) E. The sequences of RAR isotypes are highly con-
served, but subtle differences in the LBD give rise to distinct ligand
binding pocket architectures, allowing for the design of isotype-
specific retinoids.14,15 In addition, alternative splicing of primary
RAR transcripts generates, for each RAR isotype, subtypes with dif-
ferent A and B domains linked to the RARa-, RARb- and RARc-
specific core C, D, E and F domains.
The activation mechanism of the RARs (and RXRs) by retinoids
has been studied, in detail, by determination of a number of crystal
structures of the LBDs. Upon retinoid binding to the LBD, a confor-
mational change occurs allowing heterodimerisation to an RXR
partner, and subsequent binding to DNA sequences known as reti-
noic acid response elements (RAREs).4,10,16–18 A ‘mouse-trap’ pro-
cess is thought to occur during retinoid binding to the RARs, inwhich the retinoid enters the pocket and associates with a cluster
of polar residues at the end, facilitating a conformational change
which brings the C-terminal helix 12 (H12) to enclose the ligand
inside the pocket.10 The interaction between H12 and the retinoid
ligand is particularly important, since the holo positioning of H12
forms a binding surface (AF-2) that binds coactivators.10,19,20 Effec-
tive stabilization of H12, therefore, leads to the promotion of gene
transcription, and indeed, optimization of this interaction has
become an important aim for the design of synthetic retinoids.21
The molecular structure of natural and synthetic retinoids can
be described in terms of three distinct regions: a polar region (typ-
ically a carboxyl moiety) required for association with the polar
cluster at the base of the pocket, a short linker that increases the
length of the retinoid and can incorporate additional functionality
for isotype-specific binding, and a hydrophobic region for interact-
ing with H12 and the strongly hydrophobic opening to the binding
pocket.21,22 In recent molecular docking studies and receptor-bind-
ing assays, we showed that ATRA is able to bind to each of the RARs
via a number of conformations with respect to the s-cis and s-trans
orientations around formal single bond connections between dou-
ble bonds. Indeed, a bent conformation with a single s-cis bond
rotation about the C7–C8 alkene was the preferred conformation
over the more linear, all-trans conformation frequently thought
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ported by employing a novel clustering conformer analysis
approach which is ideal for examining conformationally-flexible
ligands bound to protein receptors.23,24
The length and shape of synthetic retinoid molecules signifi-
cantly affects biological activity.9 Polar interactions with the car-
boxyl moiety are important for anchoring the retinoid within the
pocket, but the contributions to biological activity and RAR-type
selectivity of more-subtle substituent and conformational proper-
ties of ligands is not well understood. A strategy for the design of
RARa-selective agonists has been the incorporation of a hydrogen
bond accepting moiety in the centre of the molecule to form a
hydrogen bond with the RARa-specific residue, Ser232.14,20,21,25
Furthermore, the greater space available in the binding pocket of
RARb has implications for the design of synthetic compounds with
greater specificity for this RAR type.
To probe the relationships between structure and function of
synthetic retinoid-like molecules we have used compounds built
around a central 2,4-disubstituted thiazole linker; this thiazole
sub-structure imposes a slight twist in the overall shape of the
molecule which may mimic the preferred binding conformation
of ATRA23 and may confer selectivity for RARa via interactions with
Ser232.26–28 Members of this synthetic retinoid series (designated
GZ, the synthesis of which is reported previously29) have either
polyalkoxyalkyl (GZ18), phenyl (GZ24 and the ester GZ22) or
1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphthyl (GZ25 and the
ester GZ23) hydrophobic regions (Fig. 1). The angle of the 1,1,4,4-
tetramethyl-1,2,3,4-tetrahydronaphthalene (TTN) hydrophobic
region with respect to the rest of the retinoid structure could
favour orientation towards the larger cavity specific to the ligand
binding pocket of RARb;30 indeed, GZ18 has been reported previ-
ously as an RARb2-specific retinoid.31 Furthermore, the increased
rigidity compared to ATRA, preorganization and lipophilicity of
these types of compounds (particularly GZ23 and GZ25) could have
entropic and enthalpic benefits for RAR binding,21,32 properties
that would make the GZ series an ideal platform for the design of
RAR-specific ligands as novel retinoid-based drugs.
The aim of this study was to test these predictions for the bind-
ing activity and specificity of synthetic retinoids based around the
use of a central thiazole linking the carboxyl and non-polar ends.
To do this, a molecular docking approach33 was used to determine
the theoretical binding modes of these compounds, and their pre-
dicted activity was tested via a ligand-binding assay dependent
upon both ligand binding and coactivator recruitment, and com-
pared with biological assays of different types.2. Results and discussion
2.1. Molecular modeling, docking and binding analysis
To predict the suitability of GZ18, GZ24 and GZ25, and the cor-
responding esters GZ22 and GZ23, for binding to the RARs, the
molecular docking method we described previously was used.23
This involved an initial, semi-empirical calculation of the confor-
mational distribution of each compound to indicate the low energy
conformations that the ligand can adopt, and to provide starting
points for the molecular docking calculations used to predict the
possible binding modes when complexed with the RAR LBDs. A
widely-employed docking strategy involves using a number of
input conformations for each ligand, rather than a single, low
energy conformation and allowing maximum ligand flexibility in
each independent docking simulation. This approach enables a
more complete assessment of the potential conformational space
that can be occupied by the ligand when bound to a target, and
improves the probability of finding a global energy minimum.34–36Accordingly, the molecular structure of each GZ retinoid was gen-
erated and used as the basis for a conformational distribution cal-
culation using the AM1 force field.37,38 For each low energy
conformation generated, the central thiazole linker was found to
be coplanar with the benzoate polar region. The phenyl and TTN
hydrophobic region of the aryl-substituted retinoids (GZ22, GZ23,
GZ24, GZ25) exhibited a 40 dihedral angle with respect to the rest
of the molecule (Fig. 2A) but the glycol hydrophobic region of GZ18
exhibited a high degree of conformational flexibility (all starting
conformations for the docking, and X-ray crystal structures of
GZ18, GZ22 and GZ23 are shown in the ESI).
Each starting conformation was then docked using GOLD39 into
the receptor binding sites utilising structures derived from the
highest resolution crystal structures of RARa,20 RARb30 and RARc10
available in the PDB. From each input conformation of each ligand,
three to ten docking solutions were returned and then examined
individually before clustering (see ESI).
2.1.1. Key interactions
The RAR binding pocket is highly hydrophobic and the interac-
tions formed between the protein and the retinoid ligand are,
therefore, mainly hydrophobic in nature (Fig. 2B).15,30 Conversely,
a cluster of polar residues at the end of the pocket (Lys236,
Arg278 and Ser289 in the case of RARc) perform an important role
in guiding the retinoid into the pocket via the carboxylate.10 This,
in turn, forms a salt bridge and hydrogen bonding interactions with
this polar cluster that are important for high binding affinity.23 The
most important ligand-binding motif in regards to transcriptional
activation activity is the interaction with H12 because ligand-
dependent stabilisation of this helix in the holo position is required
for coactivator recruitment.11,20,40 H12 is also mainly hydrophobic
(Fig. 2C) and is key in the interaction (principally via interactions
with Met402, Ile412, Met415 and Leu416 in RARc) with the
hydrophobic region of the retinoid.
2.1.2. RARa
The docking analysis clearly showed a hydrogen bonding inter-
action (2.7–3.0 Å) between the thiazole nitrogen and Ser232 (Fig.
3A). This interaction forces the thiazole ring to be oriented with
the nitrogen pointing upwards in all docking solutions; a position-
ing which facilitates interactions between the hydrophobic region
and H12. In addition, the positioning of the benzoate polar region
was similar for all solutions for each GZ retinoid. In the case of
GZ25, each of the calculated docking poses (13 solutions were
returned) were similar (Fig. 3A), apart from a single pose which
exhibited an alternative positioning of the hydrophobic region
which was orientated directly towards H12. This enhances interac-
tions with Met406 on H12 (3.5 Å compared to 4.2 Å) but causes a
steric clash with Ile410 and sacrifices contacts with the bottom
of the pocket, particularly with Leu305 (4.3 Å compared to 3.2 Å).
Overall, our results show that GZ25 is well-suited to the binding
pocket of RARa.
In contrast, the hydrophobic regions of GZ18, GZ24 and GZ25
display marked differences in the extent of interactions with
H12. The much larger TTN hydrophobic region of GZ25 formed
more-extensive hydrophobic interactions (Fig. 3B) than GZ18 and
GZ24, particularly with Met406, which requires stabilization to
maintain the closed, holo, conformation of the loop region between
H11 and H12.10,19 The hydrophobic region of GZ18 adopts a num-
ber of different conformations because of the high flexibility of this
region (Fig. 3C). This flexibility may impose a significant entropic
penalty upon binding to this relatively fixed binding pocket, partic-
ularly in comparison to the more rigid, preorganized structures of
GZ24/GZ25. Moreover, while the phenyl group of GZ24 was unable
to associate with the majority of the hydrophobic residues at the
opening of the pocket like the TTN of GZ25, the docking simulation
Fig. 2. Modelling the interaction between GZ25 and RARc. A, Lowest energy conformation of GZ25 according to in vacuo AM1 conformation distribution calculations. B,
Ligand interaction diagram of the highest scoring docking solution of GZ25 in the RARc (PDB: 2LBD) binding pocket. The hydrophobicity surface of the binding pocket is
shown, and highlights the pocket’s predominantly hydrophobic nature. A cluster of polar residues (Lys236, Arg278 and Ser289, in RARc) at the end of the pocket anchor the
retinoid via the carboxylate. Hydrogen atoms are omitted from this and all following images for clarity. C, Key residues involved in the interaction between H12 (RARc) and
the retinoid hydrophobic region. Stabilization of this helix is key to providing a suitable platform for the transcription of RAREs via AF-2.
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Fig. 3. Modeling the interactions between GZ series retinoids and RARa. A, Highest scoring docking pose (green) of GZ25 docked into RARa (PDB: 3KMR). A single docking
solution (pink) also indicated an alternative positioning of the hydrophobic region in which the TTN ring system is oriented upwards directly towards H12. B, Comparison of
the highest scoring docking poses of GZ18, GZ24 and GZ25 in RARa. C, Structural overlay of each docking solution (50 solutions) of GZ18 in RARa. D, Highest scoring docking
solutions of GZ22 and GZ23 in RARa.
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pocket of RARa compared to GZ18. Accordingly, we would expect
GZ25 to exhibit the highest binding affinity for RARa, followed
by GZ24, and then GZ18.
The esters, GZ22 and GZ23 exhibited very similar positions to
their carboxylic acid counterparts according to the docking calcu-
lations. The hydrophobic regions formed similar contacts with
H12 and the highly nonpolar opening to the pocket, and the thia-
zole linker is well positioned for hydrogen bonding to Ser232.
However, the ethyl ester moiety occupies a slightly different posi-
tioning compared to the carboxylate of the other retinoids, in
which the ethyl group is pushed into a small cavity formed
between Ser287 and Lys234 (Fig. 3D). This positioning is not unfa-
vorable, per se, however, the result is to slightly increase the dis-
tance to the guanidine moiety of the key polar residue Arg276
(3.1 Å for GZ23 versus 2.8 Å for GZ25), and inhibits the ability
the form a hydrogen bonding interaction with the Ser287 sidechain
hydroxyl. Therefore, based on these findings, the esters GZ22 and
GZ23, would be expected to exhibit reduced binding affinity for
RARa compared to the corresponding acids, GZ24 and GZ25.
2.1.3. RARb
The ligand binding pocket of RARb is significantly larger than in
RARa or RARc (503.5 Å3 versus 429.4 Å3 for RARc) because of the
additional cavity around the opening of the pocket (Fig. 4A).15,30
RARb-specific ligands have been designed by incorporating largerhydrophobic regions that can fill this cavity.21,30 When the car-
boxylic acids, GZ18, GZ24 and GZ25, were docked into RARb, a
broader range of docking poses was obtained in comparison to in
RARa. While the positioning of the polar region was fairly similar
in each solution, in RARb, the thiazole ring was oriented with the
nitrogen pointing upwards or downwards. Consequently, this ori-
entates the hydrophobic region either upwards towards H12, or
downwards towards the RARb-specific cavity. The preference of
each ligand for these two orientations was assessed by examining
each docking solution individually (see ESI). GZ18 favored orienta-
tion of the hydrophobic region downwards, presumably because
this allows a fully extended conformation of the glycol structure.
This orientation may, however, sacrifice interactions with H12,
thus suggesting that GZ18 may be a RARb-specific retinoid,31 but
one that is less capable of stabilizing H12 for coactivator
binding.19,41
GZ24 also docked exclusively with the hydrophobic region
pointing downwards towards this specific cavity, though the
shorter phenyl hydrophobic region formed fewer and weaker con-
tacts with this area of the binding pocket (distance to Ile380: GZ18
= 3.3 Å, GZ24 = 5.2 Å, distance to Val302: GZ18 = 3.3 Å, GZ24 = 4.6
Å), suggesting that GZ24 will have a lower affinity for RARb than
GZ18.30 In contrast, GZ25 exhibited an almost complete preference
for the hydrophobic region to be pointed upwards towards H12,
presumably since the much larger size of this structure mediates
particularly strong contacts with this helix. Given this, one can
Fig. 4. Interactions between the GZ retinoids and RARb and RARc. A, Highest scoring docking solutions of GZ18, GZ24 and GZ25 in RARb. B, Highest scoring docking solutions
of GZ18, GZ24 and GZ25 in RARc. C, Comparison between the highest scoring docking solutions of GZ25 and ATRA in RARb.23 D, Comparison of the carboxylate positioning of
the highest scoring docking solutions of GZ25 and ATRA in RARb.
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fic binding to RARb. Also, as in RARa, the esters, GZ22 and GZ23,
exhibited similar docking poses to the corresponding carboxylic
acids, GZ24 and GZ25, though the ester group elicits weaker polar
interactions with the polar cluster at the end of the pocket.
Reduced binding affinity for the esters was, therefore, predicted
based on these docking results.2.1.4. RARc
As with RARa, each GZ retinoid exhibited docking poses in the
binding pocket of RARc where the thiazole ring was oriented with
the nitrogen atom pointing upwards, presumably because the
opposite orientation would elicit unfavorable clashes between
the hydrophobic region and the bottom of the pocket. Furthermore,
GZ18, GZ24 and GZ25 each adopted similar poses to those
observed in RARa (Fig. 4B); however, GZ25 was positioned slightly
lower in the pocket to avoid clashes with Ala234 and Leu271
around the middle of the top surface of the binding pocket. The
positioning was particularly favorable for GZ25, and the hydropho-
bic region filled the wider opening of the binding pocket well,
forming more extensive hydrophobic contacts with Met402 (3.4
Å) and Leu416 (3.2 Å) on H12 when compared to GZ18 (5.6 Å
and 4.8 Å, respectively) and GZ24 (5.3 Å and 4.7 Å, respectively).
However, this lower positioning resulted in clashes between the
thiazole sulfur and the RARc-specific residue Met272, and between
the thiazole methyl and the nearby Ile275. This observation maysuggest that the central thiazole linker is less suited to RARc than
RARa/b. Similarly to RARa, the GZ22 and GZ23 esters adopted sim-
ilar poses in the RARc LBD to their carboxylic acid counterparts,
but the ester groups formed poorer contacts with the polar cluster
at the end of the pocket. This was particularly apparent with GZ23,
whose ethyl group was forced away from the polar cluster and
directly towards Cys237 on H3, resulting in a strong clash. There-
fore, GZ22 and GZ23 may well exhibit reduced binding affinity
for RARc compared to the corresponding carboxylic acids.2.1.5. Binding of GZ25 compared to ATRA
There was a high degree of similarity between the highest scor-
ing docking solutions for GZ25 and ATRA (Fig. 4C).23 The cyclohex-
enyl hydrophobic region of ATRA was twisted from the continuity
of the polyene chain at almost the same angle as between the
planes of the GZ25 hydrophobic region and the linker thiazole ring.
However, the increased size of the hydrophobic, linker and polar
regions of GZ25 broadly means that GZ25 fills the pockets of the
RARs more completely than ATRA and, particularly in the case of
the smaller RARa/c, elicits more extensive contacts with the bot-
tom of the pocket. The carboxylates of GZ25 and ATRA show some
differences; while the ATRA carboxylate is oriented at an angle that
benefits both hydrogen bonding with Ser280 and salt bridge for-
mation with Arg269, that of GZ25 is positioned slightly further
from Ser280 (3.4 Å versus 2.9 Å) and at a less favorable angle for
hydrogen bonding (Fig. 4D). However, this is compensated for by
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chain amide of Phe279-Ser280.
2.1.6. Comparison of docking methods with molecular dynamics
simulation
In order to corroborate the results from the docking studies,
we conducted molecular dynamics (MD) simulations involving
the full RAR LBDs and the GZ retinoids, using GROMACS.42,43
Each of the docked structures were used as starting points for
MD simulations computed over 10 ns. These simulations showed
that, over this timescale, only very minor protein movements
were observed, indicating that the RAR PDB crystal structures
were good starting points for molecular docking calculations. A
comparison (Fig. 5) between the docked and MD binding poses
for GZ24 and GZ25 (other compounds shown in the ESI) in each
of the RARs showed that the ligand binding poses from MD gen-
erally matched those from the docking very well, with an excep-
tion being the docking versus MD results for GZ22 in RARb andFig. 5. Comparison between the docking binding poses (green) and the MD bRARc. In this case, the MD pose ignored interactions between the
carboxy moiety of the ligand and the polar cluster, and instead,
moved the hydrophobic region closer to the hydrophobic open-
ing of the pockets. This alternative binding pose may be due to
an overestimation of the potential stabilisation gained from
interacting with the hydrophobic opening in favour of the likely
stronger (in reality) polar interactions at the opposite end of the
pocket. Therefore, given the lipophilicity of the ligands and the
well-established difficulties of methods such as MM/PBSA to
account for entropic effects, we used the MD simulations to val-
idate the docking predictions, rather than as a means to predict
the binding energies/affinities of the GZ retinoids.44 Importantly,
however, the MD versus docking comparison showed that our
molecular docking protocol provided informative and meaningful
binding poses that were directly comparable with those calcu-
lated at a higher level of theory, with the major advantage being
that docking can be completed in a fraction of the computation
time.inding poses (tan) for GZ24 (left) and GZ25 (right) in each of the RARs.
Fig. 6. Testing the ability of GZ series retinoids to bind RARa (A), RARb (B) and RARc
(C) and recruit coactivator.
H. Haffez et al. / Bioorganic & Medicinal Chemistry 26 (2018) 1560–1572 15672.2. Ligand-receptor assay
The main conclusions and predictions from the computational
binding studies are that: 1) GZ25 would exhibit greater binding
affinity for RARa/b/c than each of the other acids, GZ18 and
GZ24, and the esters GZ22 and GZ23; 2) each of the GZ retinoids
may exhibit specificity for RARa due to a hydrogen bonding inter-
action with Ser232; 3) the TTN hydrophobic region of both GZ23/
GZ25 forms much more extensive contacts with H12 in each of
the RARs compared to the smaller hydrophobic regions of the other
GZ retinoids, which may well translate to improved transcriptional
activity; 4) the ethyl ester group of GZ22 and GZ23 may reduce the
strength of interaction with the polar cluster at the end of the
pocket, thus reducing binding affinity; 5) the lower positioning of
the thiazole linker in RARc may cause clashes with the bottom of
the binding pocket that could translate to reduced binding affinity;
6) GZ25 and ATRA show major similarities in overall binding con-
formation and positioning, together with some differences in polar
interactions.
These predictions were tested through a receptor-binding assay
for each RAR isotype (Fig. 6), where the assay signal is dependent
on two parameters: the binding affinity of ligand to the RAR LBD,
and the affinity of the coactivator for the ligand-LBD complex.
For this assay, binding curves and variation in level of the upper
asymptote can reflect differences in co-activator affinity for the
ligand-LBD complex; variation in affinity of ligand for LBD shifts
the midpoint (EC50) of the binding curve, whereas changes in the
level of the upper asymptote may result from changes in coactiva-
tor affinity for the ligand-LBD complex alone, or in combination
with changes in affinity for ligand with LBD.23
Binding activity demonstrated variation by RAR type (Table 1,
Fig. 6). For RARa the retinoids fell into two groups: (1) ATRA,
GZ18 and GZ25 with good binding affinity (low EC50) and high
curve asymptotes (Fig. 6), (2) GZ22, GZ23, GZ24 with poor binding
(high EC50) and lower asymptotes. There was greater variability
with respect to RARb, with low EC50 and high asymptotes for
GZ23 and ATRA, high EC50 and high asymptote for GZ22, and high
EC50 with very low asymptotes for GZ24 and GZ18. For RARc,
asymptotes ranged from intermediate (GZ23/GZ24) to high
(GZ25), with a low EC50 values only for ATRA, intermediate values
for GZ25, GZ18 and GZ24, but high values for GZ23 and GZ22.
Thus, the carboxylic acids, GZ18, GZ24 and GZ25 exhibit high
affinity for each of the RARs, but with varying degrees of selectiv-
ity. GZ25 was generally more potent than ATRA for RARa/b, but the
lower affinity for RARcmay be compensated by the greater coacti-
vator recruitment activity. These results, and the overall lower
affinity of GZ24 for the RARs, was in good agreement with the
docking predictions. Conversely, GZ23, the ester of GZ25 had a sur-
prising selectivity for RARb, suggesting that the attenuation of
interactions with the polar cluster of the LBD is less detrimental
for this RAR than suggested by the docking, and may be compen-
sated by more-extensive contacts of the TTN hydrophobic region
with H12 facilitated by the larger cavity within the RARb LBD.23
The weaker binding interactions of the esters, GZ22 and GZ23,
were in general agreement with the docking studies, and the
reduced interaction of GZ23 for RARc compared to GZ25 may be
due to the predicted clash with Cys237.
The computational studies highlighted a potentially important
hydrogen bonding interaction between the thiazole nitrogen of
each GZ retinoid and Ser232 in RARa.14 While GZ25 did exhibit
the strongest binding affinity in RARa, the idea that this interaction
could confer a degree of selectivity for this isotype was not sup-
ported by the binding assay data, and this interaction may be ben-
eficial but not crucial as a driver of specificity. GZ18 exhibited
some RAR selectivity, but not as much as suggested by other stud-
ies.31 For this retinoid, confidence limits for the EC50 estimates forRARb and RARc were wide; a consequence of very low binding-
curve upper asymptotes (Fig. 6) indicating a poor ability for the
ligand-bound LBD to recruit coactivator, as predicted by the dock-
ing analyses. Overall, the wide variation between retinoids in the
upper asymptotes of the binding-curves demonstrate the impor-
tance of ligand-LBD-dependent interactions with co-activators for
retinoid activity. However, even with the type of binding assay
employed here, it may not be possible to predict the biological
Table 1
Estimated EC50 values (95% confidence ranges in parentheses) for ATRA, GZ18, GZ22,
GZ23, GZ24 and GZ25 with RARa, RARb and RARc.
Retinoid EC50 [nM] (95% confidence range)
RARa RARb RARc
ATRA 16.1 (8.8–29.4) 17.6 (15.2–20.3) 14.7 (5.4–39.8)
GZ18 15.1 (9.5–24) 56.7 (2–1591) 141.3 (25.6–778.1)
GZ22 82 (25.3–265.7) 136.3 (99.4–186.8) 383 (96.7–1517)
GZ23 88.9 (15.5–511.7) 12.1 (9.4–15.5) 847.2 (99.5–7211)
GZ24 77.5 (41.6–144.2) 77.8 (4.5–1338) 109.2 (13.8–863.7)
GZ25 8.2 (3.9–17.3) 11 (7.7–15.7) 98.9 (51.6–189.6)
Fig. 7. Biological assessment of TERA2.cl.SP12 stem cells treated with GZ series retinoid
marker) for expression of the cell-surface differentiation markers SSEA-3, TRA-1–60 and
control cells. B, Real-time PCR assay for the neuronal markers NeuroD1 (top graph) and PA
GZ25 for 3, 5 and 7 days, relative to TERA2.cl.SP12 cells treated with 0.1% DMSO vehicle
(GADPH). C, TERA2.cl.SP12 cells stained for the neuronal markers A2B5 and TUJ-1 after e
scale bar, 25 lm. D, TERA2.cl.SP12 cells stained for cytokeratin 8 (Ck-8) after exposure
1568 H. Haffez et al. / Bioorganic & Medicinal Chemistry 26 (2018) 1560–1572activity of different retinoids because retinoid responses in cellular
contexts will vary with patterns of RAR expression in combination
with different co-activators. Therefore, biological activity should be
measured directly.
2.3. Biological activity
Testing the biological activity of novel retinoids is essential for
asking whether apparent selectivity in ligand binding translates to
retinoid-dependent biological activity. The ligand binding assays
supported previous reports29 that GZ25 exhibits strong biological
activity but, for other GZ compounds, the evidence of reduceds. A, Flow cytometry (antibody staining; percentage of gated cells positive for the
A2B5. Data represent mean ± SEM, n = 3; *P < 0.05; **P < 0.01; ***P < 0.001, relative to
X6 (bottom graph) in TERA2.cl.SP12 stem cells treated with 10 lM of ATRA, GZ18 or
for 7 days; all data (mean ± SEM, n = 3) normalized to the internal reference gene
xposure to control vehicle, 10 lM ATRA, GZ18, GZ22 or GZ25 for 1, 2 and 3 weeks;
to retinoids as in C; scale bar, 25 lm.
Fig. 8. Retinoid-induced gene expression in SH-SY5Y cells treated with ATRA, GZ18
or GZ25. A, expression of RARa and RARc after 4, 8 or 12 h exposure to 10 lM
retinoids. B, expression of RARb and CYP26A1 in response to retinoid concentrations
of 1, 0.1, 0.01 and 0.001 lM for 8 h. Quantification of target mRNA was relative to
cells cultured with DMSO vehicle for the relevant time period and normalized to the
internal reference gene (ACTB). Data represent mean ± SEM, n = 3.
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biological activity. RAR-mediated mechanisms as drivers of biolog-
ical responses are poorly understood because of the confounding
effects of varying RAR specificity of different gene promoters, cel-
lular context and the potential for simultaneous and/or sequential
interactions of different RARs. Reliance on a single biological assay
is, therefore, likely to be misleading and we have used a range of
approaches to assess biological activity with respect to broad-
(neuronal differentiation phenotype) and finer-scale responses
(gene induction) for our GZ series compounds, with focus on
GZ25 and GZ18 in comparison to ATRA.
First, we examined neuronal differentiation in pluripotent
TERA2.cl.SP12 human embryonal carcinoma stem cells in response
to retinoid treatment. TERA2.cl.SP12 cells have been used in previ-
ous studies8,29 to test the ability of synthetic retinoids to induce
differentiation along a neuronal or an alternative epithelial path-
way at long in vitro timescales of up to three weeks. The response
to ATRA in these cells can be quantified through changes in the
proportion of cells expressing the specific cell surface markers,
SSEA-3, TRA-1–60 and A2B5. SSEA-3 and TRA-1–60 are epitopes
associated with stem-cell pluripotency45–47 and typically down-
regulated as a result of cellular differentiation.45 Conversely,
A2B5, a neuronal cell-membrane ganglioside antigen, is normally
upregulated as a result of neuronal differentiation.48 Using flow
cytometry, we measured the proportion of cells expressing these
differentiation markers after exposure to 10 lM of the different
GZ retinoids for 7 days and compared the results to ATRA. GZ25
was the most potent, even compared to ATRA (Fig. 7A), whereas
GZ18, GZ23 and GZ24 had very little activity compared to control
cultures. Intermediate responses were apparent in cells treated
with GZ22. Since the parent carboxylic acid (GZ24) had little activ-
ity, the response to GZ22 was a real effect of the ester rather than a
result of hydrolysis of the parent ester to the carboxylic acid.
Second, NeuroD1 and PAX6 are retinoid-induced transcription
factors involved in regulating neuronal differentiation,49,50 and
are expressed in neurons derived from TERA2.cl.SP12 stem cells.
Therefore, we examined the expression of mRNA for these tran-
scription factors in TERA2.cl.SP12 cells, which showed time-depen-
dent increases after treatment for up to 7 days after exposure to
GZ25, GZ18 or ATRA. NeuroD1 was expressed in response to
GZ25, G18 or ATRA after 5 days (GZ25 > GZ18 > ATRA), but after
7 days, expression was only maintained in response to ATRA or
GZ25 (ATRA > GZ25; Fig. 7B). With respect to the induction of
PAX6 expression, GZ25 was substantially more active than either
ATRA or GZ18 (GZ25 ATRA > GZ18).
Third, we carried out assessment of protein expression using
immunofluorescent techniques on cultures of TERA2.cl.SP12 cells
treated with retinoids. Expression of the neuronal differentiation
marker A2B5 was induced after 7 days with GZ25 or ATRA, with
greater staining intensity for the GZ25-treated cells (Fig. 7C). Over
longer timescales of up to 3 weeks, GZ25 and ATRA were also the
most effective at inducing neuronal differentiation, as shown by
immunocytochemical staining for the neuronal marker TUJ-1 (neu-
ron-specific class III b-tubulin), with a very low activity of GZ18 or
GZ22 only apparent from 2 weeks as small, scattered colonies of
TUJ-1-positive cells. In contrast, GZ18 and GZ22 were more effec-
tive at inducing the expression of the epithelial phenotype marker
cytokeratin 8, which was not detectable in cells treated with ATRA
or GZ25 (Fig. 7D).
Fourth, we examined the morphological changes (neurite
extension) and relative levels of induction of the neuronal marker
seen in the immunofluorescent experiments (Fig. 7C and D). With
ATRA and GZ25, they fitted the pattern of activity expected with
respect to changes in expression of the stem cell markers and Neu-
roD1 and PAX6 expression. In respect of epithelial differentiation
indicated by the induction of cytokeratin 8, this behavior of GZ18
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thalenyl-ethynyl)benzoic acid retinoid, EC19.8 However, EC19 is
known to be relatively selective for RARb,23 whereas GZ18 and
GZ22 showed little convincing evidence for RARb selectivity, either
with respect to ligand binding affinity or coactivator recruitment
but better selectivity for RARa. Although GZ18 has been described
by others31 as an RARb2-isoform-specific ligand, different RARb
isoforms (which vary in the A and B domains) will have the same
LBD and such an apparent specificity is likely to be an artefact of
the biological RAR-specificity assays employed. At face value and
in the context of data for EC19, these results suggest that neural
differentiation is dependent on combinatorial activity, either
simultaneously or sequentially, by RARa and RARb, with epithelial
differentiation resulting from activation of one receptor type or as
a result of a non-specific effect.
As an additional assay of biological activity, short-term changes
in expression of four genes in SH-SY5Y cells was employed; a neu-
roblastoma-derived lineage that undergoes neuronal differentia-
tion in response to retinoid treatment. The four genes assayed,
RARa, RARb, RARc and CYP26A, have RAREs associated with their
promoters and may be directly regulated by retinoids.51,52 RARa
and RARc were induced in a time-dependent manner over a 12 h
period by 10 lM retinoid, with ATRA having the greatest activity
and GZ18 and GZ25 giving lower levels of induction (Fig. 8A).
Time-courses for RARb and CYP26A1 induction after 10 lM reti-
noid treatment were more variable, but GZ18 was less active in
comparison to either GZ25 or ATRA. Dose-response experiments
over the range 1 nM to 1 lM for these latter two genes (after 8 h
treatment), indicated a dose-dependent induction of RARb with
GZ25 having greater activity than either ATRA or GZ18 (Fig. 8B).
For CYP26A1, both GZ25 and GZ18 (GZ25 > GZ18) had greater
activity than ATRA at doses <1 lM, but less activity than ATRA at
higher doses. GZ25 was clearly the most effective retinoid (GZ25
 ATRA > GZ18) at inducing RARb at all doses (Fig. 8B). RARb
expression is likely to be driven predominantly by RARb and the
relatively low activity of GZ18 contrasts with the effective activity
in the same assay of the relatively RARb-specific synthetic retinoid
EC19.23,53 In contrast, GZ18 was more effective at inducing
CYP26A1 (GZ25 > GZ18 > ATRA); given the role of CYP26A1 in
metabolizing ATRA the promotor of this gene may be less RAR
specific than the RARb promoter.3. Conclusions
The aims of this study were to combine molecular docking,
based on the conformational analysis of flexible ligands, with
ligand-coactivator binding and biological assays at different tem-
poral scales to probe the relationships between structure and func-
tion of a series of synthetic retinoid compounds built around a
central 2,4-disubstituted thiazole linker structure. Our major find-
ing was that the observed ‘super’ retinoid activity of GZ25, in par-
ticular, can be understood using the combination of tools
employed herein and especially when compared with less or
non-active derivatives of the thiazole compounds. Thus, bearing
in mind the potential uncertainties of computational predictions,
the docking studies (validated by MD) predicted that GZ25 should
be a better ligand for each of the RARs, except perhaps RARc, on the
basis of improved interactions of the bulkier hydrophobic region
with H12 and the pocket opening. The docking work also indicated
that a bulky hydrophobic region (e.g., TTN) should favor interac-
tions with H12 and coactivator recruitment, independent of ester-
ification of the carboxylate function. Conversely, the predicted
selectivity for RARa, suggested by hydrogen bonding to Ser232
from the docking studies, was not supported by the ligand binding
assays, with the possible exception of GZ18; moreover, the selec-tivity of GZ18 for RARb suggested by other reports was not sup-
ported by ligand binding studies.31 Indeed, in biological assays,
GZ25 showed strong activity, i.e., perhaps super-retinoid activity
being considerably better than ATRA with respect to inducing neu-
ronal differentiation. GZ25 may, therefore, be an ideal candidate as
a stable, highly active surrogate for ATRA. In contrast, the other GZ
synthetic retinoids had low activity in most of the biological
assays, with evidence for the induction of differentiation to non-
neuronal phenotypes. The higher than expected affinity for RARb
and good activity for coactivator recruitment shown by the ester
of GZ25 may make it a good starting point for designing novel
RAR ligands that are genuinely RARb-specific.
In terms of wider conclusions, it seems that while molecular
docking, informed by detailed conformational analysis of potential
ligands, is a powerful approach for aiding ligand design, providing
good predictive value, there are some limitations. Thus, with
respect to the design of RAR ligands, overall shape and interactions
with H12 are important for high biological activity, and ligand
affinity may be driven by polar group interactions, with interac-
tions along the length of the ligand structure apparently of lesser
importance. Uncovering the key structural and conformational
effects that govern receptor binding, and hence, the impacts on
downstream biology, demands a more detailed picture and analy-
sis of the synthetic retinoid structures versus functions, since these
depend on the physical separation and type of interactions that
operate deep within the LBD and around the entry portal.
Further work to apply this approach and develop increasingly
selective ranges of RAR-binding ligands is underway and will be
reported in due course.4. Materials and methods
4.1. Retinoid solutions
Synthetic retinoids were synthesized as reported previously,29
and ATRA was purchased from Sigma Aldrich. All compounds were
dissolved in DMSO to a concentration of 10 mM. Stock solutions
were stored at 20 C, in the dark, and defrosted in a water bath
set at 37 C prior to use.
4.2. Cell culture
Human pluripotent TERA2.cl.SP12 embryonal carcinoma stem
cells and SH-SY5Y human neuroblastoma cells were cultured and
passaged as reported previously using low lighting conditions to
minimize ATRA degradation/isomerization.8,53
4.3. Flow cytometry
The expression of specific cell surface protein markers (SSEA-3,
TRA-1–60, A2B5) on TERA2.cl.SP12 was analyzed using flow
cytometry as described previously.53 Briefly, TERA2.cl.SP12 cells,
2  105 per 25 cm2 flask, were seeded 12–24 h before treatment
with 10 lM retinoid for 7 days. The primary antibodies used were
SSEA-3 (diluted 1:10, University of Iowa Hybridoma Bank), TRA-1–
60 (diluted 1:50, Abcam) and neural cell marker A2B5 (diluted
1:40, R&D Systems). Labeled cells were analyzed in a Guave Easy-
Cyte Plus System (Millipore) flow cytometer and thresholds deter-
mining the numbers of positively expressing cells were set against
the negative control antibody, P3X.
4.4. Gene expression analysis
Real time PCR was carried out immediately after treatment on
both cell line lysates with 0.25% trypsin–EDTA. TERA-2.cl.SP12 cells
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before treatment. Cells were treated with each retinoid at a con-
centration of 10 lM for 3, 5 and 7 days. SH-SY5Y cells were seeded
at a density of 1  106 cells per 25 cm2 flask, 12–24 h before treat-
ment. Cells were treated with each retinoid at a range of concen-
trations (1, 0.1, 0.01 and 0.001 lM) and at different time scales
(2–12 h). Commercial RNA extraction kits (Qiagen) and reverse
transcription (Applied Biosystems) kits were purchased and proce-
dures used according to the manufacturer instructions. Real time
PCR was performed using the TaqMan Universal PCR
Master Mix (Life technologies) and TaqMan gene expression
system (Applied Biosystems) based on probe sets to the
specific genes to be analysed. Genecodes used are as follows:
RARb (Hs00233407_m1), CYP26-A1 (Hs00175627_m1), RARa
(Hs00940448_g1), RARc (Hs01559234_m1), PAX-6 (Hs010881
12_m1), NeuroD1 (Hs01922995_s1). GADPH (Hs02758991_g1)
and ACTB (Hs99999903_m1) were used as internal control genes
for TERA-2.cl.SP12 and SH-SY5Y, respectively.
4.5. Immunocytochemistry
TERA2.cl.SP12 cells were seeded at 5000 cells per well on poly-
D-lysine (25 lg/ml) coated cover slips in 6-well plates. Cells were
treated with each retinoid at a concentration of 10 lM for 7, 14
and 21 days (the media was changed every 3–4 days). Cells were
also treated with 1% DMSO for the same time periods as a positive
control. At the end of the treatment period, cells were fixed (4%
para-formaldehyde in PBS for 30 min at room temperature (RT)
and rinsed with PBS. One set of experiments was used for the cell
surface marker A2B5 (diluted 1:100, R&D systems), and the other
set was prepared for intracellular staining using 1% Triton-X-100
(Sigma Aldrich) in PBS as a permeabilizing agent for 10 min at
RT. Non-specific labeling was blocked by incubation with a solu-
tion of 1% goat serum (Sigma Aldrich) containing 0.2% Tween-20
(Sigma Aldrich) in PBS for one hour at RT. The primary antibodies
b-III tubulin antibody (TUJ-1) (1:200, Affymetrix eBioscience) and
CK-8 antibody (1:500, Affymetrix eBioscience) were diluted in
blocking solution and incubated with the cells for 1 h at RT. After
washing three times for 15 min with PBS, cells were incubated
for 1 h in the dark with anti-mouse FITC-conjugated secondary
antibody IgM (1:128, Sigma Aldrich) for A2B5 staining, and anti-
mouse Alexafluor 488 IgG (1:600, Invitrogen) for TUJ-1 and CK-8
staining. Hoechst 33,342 nuclear staining dye (1:1000, Molecular
Probes) was dissolved in blocking solution after the secondary
antibody staining step for nuclear staining.
4.6. Imaging
Immunocytofluorescent images of fixed cells were visualized
using a Leica SP5 confocal microscope. Scale bars are shown at
25 lm.
4.7. Receptor binding assays
The binding interaction of each retinoid with RARa, b and c
were determined in vitro by time-resolved fluorescence resonance
energy transfer (TR-FRET) using the LanthaScreen TR-FRET RARa,
RARb, and RARc co-activator assays according to the manufac-
turer’s (InvitrogenTM) instructions.23 This uses a terbium-labeled
anti-GST antibody, a fluorescein-labeled co activator peptide, and
RARa/b/c ligand-binding domains (LBD) that are tagged with glu-
tathione-S-transferase (GST) in a homogenous assay format. All
experiments were performed in black, 384-well low-volume plates
in the dark at RT with a 4 h incubation time. The final assay volume
was 20 lL and all dilutions were carried out using TR-FRET assaybuffer, with a final DMSO concentration of 1%. A mixture of either
3.5 nM GST-RAR-a-LBD or 2.5 nM GST-RAR-b-LBD or 3 nM GST-
RAR-c-LBD with 62.5 nM Tb-anti GST antibody and 30 lM fluores-
cein-labeled peptide and retinoid or DMSO control was added to
each of the wells. Each ligand assay was performed in duplicate
and measured using a PHERAstar FS Microplate Reader (BMG Lab-
tech, Ortenberg, Germany) with instrument settings as described
in the manufacturer’s instructions for LanthaScreen assays. The
TR-FRET signal was expressed as the ratio of the signals at 520
nm and 490 nm. The data were fitted to a three-parameter
ligand-binding curve using SigmaPlot (version 12.5, Systat Soft-
ware Inc., San Jose CA) and normalized to the lower asymptote of
each binding curve. The TR-FRET binding assay produces symmet-
rical sigmoid curves varying in location of the mid-point (EC50) and
upper asymptote. Since the assay involves interactions between
ligand and LBD, and ligand-dependent interactions between the
LBD and fluorescein-labeled co activator, the binding assay data
were interpreted by simulating these coupled chemical reactions
using the biochemical simulator COPASI version 4.3.23,54
4.8. Molecular modeling
Molecular structures of all compounds (ATRA, GZ18, GZ22,
GZ23, GZ24 and GZ25) were generated using Spartan ‘14
(Wavefunction Inc., Irvine, CA).37 These were minimized using a
molecular mechanics force field, followed by semi-empirical
molecular orbital (AM1) methods to generate a conformer distribu-
tion in vacuo. The generated conformations of each compound
were then checked by re-minimization using a higher level of
theory (Hartree-Fock, 3-21G) to ensure that the generated con-
former distribution was realistic. All possible conformations of all
compounds were saved as .mol2 files for use in the docking studies.
4.9. Docking
Docking calculations were conducted according to a previously
reported procedure,23 in which all of the output conformations
from the molecular modeling studies were docked into RARa, b
and c, in order to more-completely sample the available conforma-
tional space of the ligand.55 Docking calculations were conducted
using GOLD.39
Crystal structures were retrieved from the RCSB protein data
bank as PDB files (3KMR20 for RARa, 1XAP30 for RARb and 2LBD10
for RARc). The bound ligands were removed from the structures,
and used only as a positional reference. Hydrogen atoms were
added to protein residues using the default GOLD settings.39 All
solvent molecules were removed. Active site residues were
selected within a diameter of 15 Å, measured from a selected point
at the center of the ligand position, and therefore included the
entire binding pocket. It is important to note that the carboxylic
acid moiety was considered as a carboxylate, rather than proto-
nated, as this is more realistic with respect to physiological pH,
and to the likelihood that the negative charge is stabilized by the
closely positioned polar residues in the binding pocket.56,57
ChemScore was chosen as the most appropriate target function
in the genetic algorithm to balance between computational speed
and the reliability of the GOLD predictions for the possible confor-
mations of the different retinoids binding to RARs.58 The genetic
algorithm parameters were based on previous examples of docking
hydrophobic ligands: population size 100; number of islands 5;
niche size 2; selection pressure 1.1; migrate 2; and number of
operators 100,000.59 A search efficiency of 200% was used, which
dictates maximum ligand flexibility. During the docking process
no limit was placed on the number of binding poses retained,
though typically 3–10 solutions were retained by the genetic
algorithm.
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The docked structures of each ligand with the three isoforms of
RAR were used as starting models. Any remaining solvent mole-
cules were removed. Missing loops were built with MODELLER
(v9.19)60,61 via UCSF Chimera.62 The final protein structures cov-
ered residues 182–415 for RARa,20 182–411 for RARb,30 and
188–419 for RARc.10
The ligands were parameterised using Gasteiger point charges
in the AMBER ff99sb63 forcefield for simulation using Antecham-
ber,64 and prepared for GROMACS using ACPYPE.65 The complexes
for each isoform-ligand pair were then prepared in GROMACS,42
parameterised in ff99sb and neutralised with sodium and chloride
ions to a final concentration of 0.1 M, prior to being subject to min-
imisation and equilibration. Briefly, a steepest descent gradient
was used to minimise the complexes, which all converged on an
Fmax <1000 kJ mol1 nm1 in less than 1200 steps. The complexes
were then subject to 200 ps equilibration in the NVT ensemble
using a 2 fs timestep and Nose-Hoover temperature coupling at
300 K; all atoms were subject to position restraints. Subsequent
equilibration in the NPT ensemble was also conducted under posi-
tion restraints at a 2 fs timestep, with Parinello-Rahman barostat at
1 bar. Finally, position restraints were released and two parallel
production MD simulations were conducted for a 10 ns time per-
iod. The g_mmpbsa43 package was used to calculate binding ener-
gies between ligand and protein, and to quantify per-residue
contributions to binding. The final 2 ns of converged simulation
time was used for each of the simulations, totalling 201 snapshots
from 8 to 10 ns.
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